Having trouble finding Bimatoprost at your pharmacy? Learn why this glaucoma and eyelash growth medication can be hard to find in 2026 and what you can do.
You've got your prescription in hand, but when you show up at the pharmacy, the answer is the same: "We don't have it right now." If you've been struggling to fill a prescription for Bimatoprost — whether it's the generic version or the brand-name Lumigan — you're not imagining things. Many patients across the country have reported difficulty finding this medication in stock throughout 2025 and into 2026.
Bimatoprost is an important medication used to treat glaucoma, ocular hypertension, and eyelash hypotrichosis (inadequate eyelash growth). When you can't find it, the stakes are real — untreated glaucoma can lead to permanent vision loss. So let's break down why Bimatoprost can be hard to find and what you can do about it.
Bimatoprost is a prescription eye medication that belongs to a class of drugs called prostaglandin analogs. It works by increasing the outflow of fluid from the eye, which lowers intraocular pressure (IOP). High eye pressure is a major risk factor for optic nerve damage and vision loss from glaucoma.
Bimatoprost is sold under several brand names:
The medication was first approved by the FDA in 2001 and is manufactured by AbbVie (formerly Allergan). Generic versions of Bimatoprost ophthalmic solution are also available from several manufacturers.
For a deeper dive into what this medication does and how to take it, check out our guide on what Bimatoprost is, its uses, and dosage.
There are several reasons you might be having trouble filling your Bimatoprost prescription. Here are the most common ones:
Even though there is no formal FDA-listed shortage for Bimatoprost as of early 2026, many pharmacies experience intermittent stock issues due to manufacturer backorders. The pharmaceutical supply chain is complex, and disruptions at the manufacturing or distribution level can create gaps in availability at your local pharmacy.
The 0.01% concentration of Bimatoprost has been particularly affected by supply constraints. While Amneal Pharmaceuticals received FDA approval in late 2025 for a generic version of Bimatoprost 0.01%, it takes time for new generic supplies to fully reach pharmacy shelves nationwide.
Bimatoprost is a specialty ophthalmic product that requires sterile manufacturing conditions. Not every generic drug maker has the facilities or expertise to produce ophthalmic solutions. With fewer manufacturers in the market, any disruption to even one supplier can create noticeable shortages across the country.
Many chain pharmacies use automated inventory systems that order medications based on recent demand. If your pharmacy doesn't regularly fill Bimatoprost prescriptions, they may not keep it in stock. This is especially common at large chain pharmacies that prioritize higher-volume medications.
Some insurance plans require patients to use specific pharmacies, mail-order services, or particular formulations. These restrictions can funnel demand to certain pharmacies while leaving others out of the supply chain entirely. If your plan requires the brand-name Lumigan but the pharmacy only stocks the generic, or vice versa, you may face additional delays.
The good news is that there are practical steps you can take to locate your medication faster:
Medfinder helps you search for pharmacies that currently have Bimatoprost in stock near you. Instead of calling pharmacy after pharmacy, you can check availability online and save yourself time and frustration. Learn more in our guide on how to find Bimatoprost in stock near you.
Independent pharmacies often have more flexible ordering systems than large chains. They may be able to special-order Bimatoprost from a different wholesaler or carry concentrations that chain pharmacies don't typically stock. Call a few local independent pharmacies and ask if they can order it for you.
If you absolutely cannot find Bimatoprost, talk to your eye doctor about alternatives. Other prostaglandin analogs like Latanoprost (Xalatan), Travoprost (Travatan Z), and Tafluprost (Zioptan) work in a similar way and may be easier to find. Read our full guide on alternatives to Bimatoprost for more options.
If you have open-angle glaucoma and are tired of dealing with daily eye drops, ask your ophthalmologist about Durysta — a Bimatoprost implant that is placed directly in the eye during a quick office procedure. It slowly releases medication over time, eliminating the need for daily drops. This won't help with availability of the drops, but it may be a better long-term solution for some patients.
Cost can sometimes be a barrier that makes it seem like the medication is "unavailable." If price is the issue, there are options. AbbVie offers a co-pay savings program for Lumigan, and patient assistance programs are available for those who qualify. Discount cards from GoodRx and SingleCare can bring the generic price down to as low as $1 to $57. Our post on how to save money on Bimatoprost has the full breakdown.
Finding Bimatoprost shouldn't feel like a scavenger hunt, but for many patients in 2026, it does. Supply chain challenges, limited generic manufacturers, and pharmacy stocking patterns all play a role. The most important thing is to not skip your medication — untreated glaucoma can cause irreversible vision loss.
If your pharmacy doesn't have Bimatoprost, use tools like Medfinder to find it nearby, talk to your doctor about alternatives, and explore savings programs to make sure cost isn't standing in your way. You have more options than you might think.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
